Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Total Current Assets
All assets expected to be converted to cash or used up within one year.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 125.0% from a year ago
Total current assets stood at $3.41M at the end of Q1 FY2026, up 125.0% from a year earlier and down 34.2% from the prior quarter. Over 3 fiscal years it compounded at -2.3% a year.
Context
- Total current assets amounted to 31.4% of total assets at the end of Q1 FY2026, down 68.6 pp from a year earlier.
- Total current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +125.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 5.18M USD
- Year-over-year change
- +398.4%
- 4-year CAGR
- +0.4%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.18M | +398.4% |
| FY2024 | 2024-12-31 | 1.04M | -75.9% |
| FY2023 | 2023-12-31 | 4.31M | -22.5% |
| FY2022 | 2022-12-31 | 5.56M | +9.2% |
| FY2021 | 2021-12-31 | 5.09M | — |
Total Current Assets vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's Mar 2026 total current assets of $3.41M is the lowest of the 2 companies compared; the peer median is $27.91M.
- Its year-over-year change of +125.0% is the lowest of 2, against a peer median of +165.7%.
- Total current assets amounts to 31.4% of total assets for LIXT, versus a peer median of 90.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $27.91M | +165.7% | +15.1% | 90.4% | |
| Mar 2026 | $3.41M | +125.0% | -2.3% | 31.4% | |
| Peer median (excluding LIXT) | $27.91M | +165.7% | +15.1% | 90.4% | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.